查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1470458

生物模擬市場：按產品、交付模式、最終用戶、應用分類 - 2024-2030 年全球預測

Biosimulation Market by Offering (Services, Software), Delivery Model (Ownership Models, Subscription Models), End-User, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年生物模擬市場規模為38.1億美元，預計2024年將達44億美元，2030年將達98.7億美元，複合年成長率為14.55%。

生物模擬結合了數學、生物學和電腦程式設計來創建模擬來檢驗假設、預測結果並探索生物技術的新可能性。生物模擬透過模擬基因表現、新陳代謝和細胞生長等生物現象，幫助研究人員更好地了解生命的複雜性並開發醫療保健新產品。隨著新藥和藥品開發的不斷進步，以及政府專注於將數位化位技術整合到製藥和生物製藥領域，對生物模擬系統的需求不斷增加。然而，開發模擬軟體的高成本阻礙了市場的成長。由於電腦輔助設計（CAD）和虛擬實境（VR）技術的日益融合，以及人工智慧（AI）和機器學習（ML）在新模擬軟體開發中的進步，生物模擬市場預計將擴大馬蘇。

主要市場統計
基準年[2023] 38.1億美元
預測年份 [2024] 44億美元
預測年份 [2030] 98.7億美元
複合年成長率（%） 14.55%

生物模擬軟體為模型建構、模擬、分析和視覺化提供平台，其使用正在不斷增加。

合約服務由專業公司和研究組織提供，為其客戶提供生物模擬專業知識，支援模型開發、模擬研究、資料分析和解釋。內部服務是在組織或研究機構內執行的生物模擬服務。分子建模和模擬軟體專注於對蛋白質、核酸和小分子等分子的行為進行模擬和建模。它用於研究分子之間的相互作用和結構變化，並預測結合親和性等特性。 PBPK建模和模擬軟體旨在模擬藥物和化學物質的生物分佈、吸收、代謝和排泄。 PK/PD、建模和模擬軟體影響藥物的藥物動力學和動態特性，幫助預測藥物濃度和暴露-反應關係，並最佳化給藥方案。毒性預測軟體專注於預測化合物的潛在毒性。計算模型用於評估接觸特定化學物質和藥物的安全性和潛在風險。臨床試驗設計軟體支援臨床試驗設計和最佳化，模擬各種臨床試驗場景，評估統計功效，最佳化樣本大小，以提高臨床試驗的效率和有效性。

交付模型：生物模擬傾向於支援為使用者提供完全控制的所有權模型。

生物模擬的所有權模型允許使用者購買軟體和服務，並完全控制軟體及其使用方式。在生物模擬所有權模型中，使用者購買軟體的永久許可證，並被授予無限期使用該軟體的權利。在訂閱模式中，使用者支付經常性費用才能存取和使用軟體和服務。在此模型中，使用者通常不擁有該軟體，但可以持續存取最新版本和更新。

最終用戶：製藥和生物技術公司擴大採用生物模擬

委外研發機構(CRO) 經常利用生物模擬來支援客戶的藥物發現和研發流程，包括使用生物模擬技術進行分子建模、PK/PD 建模、毒性預測等。製藥和生物技術公司在其藥物開發平臺中廣泛採用生物模擬。包括美國食品藥物管理局(FDA) 和歐洲藥品管理局 (EMA) 在內的監管機構在核准藥品上市之前評估藥品的安全性和有效性方面發揮著重要作用。監管機構使用生物模擬來評估藥物的風險效益狀況、最佳化研究設計並在醫藥品認證過程中做出明智的決定。學術機構和政府機構等研究組織使用生物模擬來提高科學知識並進行高級研究。研究人員使用生物模擬工具和技術來建模和模擬複雜的生物系統，探索假設，並深入了解基本的生物過程。

將生物模擬的應用擴展到應用藥物開發

生物模擬提供有關藥物的藥物動力學 (PK) 和動態(PD) 特性的見解和預測，以最佳化給藥方案、預測目標組織中的藥物濃度以及候選藥物的潛在功效和安全性，它在藥物開發中發揮重要作用。 PBPK 和 PK/PD 建模等生物模擬技術可支援藥物開發中的明智決策。生物模擬支持臨床試驗的設計和最佳化，並能夠預測和評估藥物和化合物的吸收、分佈、代謝、排泄和毒性特性。生物模擬可以在藥物開發過程的早期識別潛在的 ADME/Tox 問題，從而減少廣泛的動物測試的需要並提供對潛在風險的洞察。 PK/PD建模和模擬可以預測藥物暴露和反應性之間的關係。生物模擬透過採用分子建模和模擬技術來支持先導化合物的識別和最佳化。幫助篩檢和評估潛在的候選藥物，預測與目標分子的結合親和性，並最佳化化學結構以提高效力和選擇性。生物模擬技術可以幫助識別和檢驗潛在的藥物標靶。生物模擬透過建模和模擬藥物分子與目標蛋白之間的相互作用，有助於評估靶向特定蛋白的可行性和潛在有效性。

區域洞察

美洲地區是生物模擬市場高度發展的地區。這是由於美國現有主要參與者的存在以及他們對推進模擬軟體的持續努力。 FDA（美國食品藥物管理局）、EMA（歐洲藥品管理局）和加拿大衛生署等監管機構的成立，確保藥物開發和臨床試驗的安全性和效率，為亞太地區的市場成長做出貢獻。 。就歐洲、中東和非洲地區而言，英國、德國和法國對藥物開發和臨床試驗的投資增加正在推動模擬軟體和服務的採用。亞太地區慢性病的增加預計將促使各國政府和監管機構加強對藥物開發的資助力度，為生物模擬市場的開拓提供平台。針對藥物研發 (R&D) 活動的各種舉措的存在，例如澳洲藥物發現計劃和醫學研究商業化計劃，正在擴大生物模擬在亞太地區的使用。

FPNV定位矩陣

FPNV定位矩陣對於評估生物模擬市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對生物模擬市場中供應商的現狀進行深入而詳細的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4. 競爭評估和情報：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況和製造能力進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.生物模擬市場的市場規模與預測是多少？

2.在生物模擬市場的預測期間內，有哪些產品、細分市場、應用和領域需要考慮投資？

3.生物模擬市場的技術趨勢和法規結構是什麼？

4.生物模擬市場主要廠商的市場佔有率為何？

5. 進入生物模擬市場的合適型態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 專注於個人化醫療研究
      • 監管部門核准使用生物模擬加速安全藥物開發
    • 抑制因素
      • 與生物模擬安裝和技術開發相關的價格上漲
    • 機會
      • 模擬解決方案不斷進步，以增強新的生物療法
      • 加大藥物研發及藥物檢測投入
    • 任務
      • 複雜性和缺乏產生準確結果的意識
  • 市場區隔分析
    • 它提供什麼：增加生物模擬中軟體的使用，提供模型建構、模擬、分析和視覺化平台
    • 分配模型：生物模擬中越來越傾向於所有權模型，以便為使用者提供完全控制
    • 最終用戶：擴大生物模擬在製藥和生物技術公司的採用
    • 應用：擴大生物模擬在藥物開發的應用
  • 市場趨勢分析
    • 對藥物開發和合作進行大量投資，以擴大生物模擬在美洲的使用
    • 政府推動亞太地區藥物研究創新技術採用的舉措
    • 臨床試驗和藥物開發活動的增加擴大了歐洲、中東和非洲地區生物模擬的範圍
  • 俄羅斯和烏克蘭衝突的累積影響
  • 高通膨的累積效應
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 法規結構分析

第6章生物模擬市場：透過提供

  • 服務
  • 軟體

第7章依分佈模型分類的生物模擬市場

  • 所有權模式
  • 訂閱模式

第 8 章生物模擬市場：依最終用戶分類

  • 合約調查機構
  • 製藥和生物技術公司
  • 監管機構
  • 調查機構

第9章生物模擬市場：依應用分類

  • 藥物開發
  • 藥物發現

第10章美洲生物模擬市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太生物模擬市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲生物模擬市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Certara 和 DNDi 聯手加快資料提交速度並加快延遲治療患者的藥物核准
    • Certara 發布用於藥物開發的 Phoenix 生物模擬模擬軟體8.4 版
    • Certara 利用人工智慧增強藥物發現的 CODEX 平台
    • Simulations Plus 推出新的整合式肺部軟體和服務包，旨在簡化藥物開發並改善患者治療結果
    • Simulations Plus 取得美國FDA 續簽 DILIsym 軟體許可證
    • Simulations Plus 建立合作夥伴關係，透過應用 AI/ML 技術設計新化合物
    • Simulations Plus 發表重新設計的 NAFLDsym QSP 軟體工具
    • Cellworks 進軍精準醫療業務，加速癌症藥物開發並重振擱置的製藥資產
    • Certara 收購 Vyasa，一家提供預測以加速科學創新的人工智慧公司
    • Applied BioMath LLC 宣布與 SpringWorks Therapeutics 合作進行多發性骨髓瘤的系統藥理學建模
    • Applied BioMath LLC 宣布繼續與攝氏度療法在發炎性腸道疾病的系統藥理學建模方面合作
    • GNS 和施維雅宣佈人工智慧合作，推動多發性骨髓瘤治療的藥物發現和臨床開發
    • Cadence 透過收購計算分子設計領域的先驅領導者 OpenEye Scientific 進軍分子模擬領域
    • 解析度 Medical 收購先健科技集團
    • Colorcon Ventures 投資人工智慧驅動的生物模擬公司 VeriSIM Life

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-2D64BA93AB17

[197 Pages Report] The Biosimulation Market size was estimated at USD 3.81 billion in 2023 and expected to reach USD 4.40 billion in 2024, at a CAGR 14.55% to reach USD 9.87 billion by 2030.

Biosimulation combines mathematics, biology, and computer programming to create simulations to test hypotheses, predict outcomes, and explore new possibilities in biotechnology. By simulating biological phenomena such as gene expression, metabolism, and cell growth, biosimulation helps researchers better understand the complexities of life and develop new products for healthcare. The increasing development of new drugs and medicines and the growing government focus on integrating digitalized technologies in pharmaceutical and biopharmaceutical sectors are elevating the need for biosimulation systems. However, the high cost associated with developing biosimulation software hampers market growth. The growing integration of computer-aided design (CAD) and virtual reality (VR) technologies, as well as advancements in artificial intelligence (AI) and machine learning (ML) for the development of new biosimulation software, is expected to expand the scope of the biosimulation market.

KEY MARKET STATISTICS
Base Year [2023] USD 3.81 billion
Estimated Year [2024] USD 4.40 billion
Forecast Year [2030] USD 9.87 billion
CAGR (%) 14.55%

Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization

Contract services are provided by specialized companies and research organizations that offer biosimulation expertise to clients, which assist with model development, simulation studies, data analysis, and interpretation. In-house services are biosimulation services conducted within an organization and research institution. Molecular modeling & simulation software focuses on simulating and modeling the behavior of molecules, such as proteins, nucleic acids, and small molecules. It is used to study molecular interactions and conformational changes and predict properties such as binding affinity. PBPK modeling & simulation software is designed to simulate the distribution, absorption, metabolism, and excretion of drugs and chemicals in the body. PK/PD, modeling & simulation software, affects drugs' pharmacokinetic and pharmacodynamic properties, helps predict drug concentrations and exposure-response relationships, and optimizes dosing regimens. Toxicity prediction software focuses on predicting the potential toxicity of chemical compounds. It uses computational models to assess the safety and potential risks of exposure to specific chemicals or drugs. Trial design software helps in the design and optimization of clinical trials and also simulates different trial scenarios, evaluates statistical power, and optimizes sample sizes to improve the efficiency and validity of clinical studies.

Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users

In the biosimulation ownership model, users purchase the software and service outright, giving them full control over the software and its usage. In the biosimulation ownership model, users purchase a perpetual license for the software, granting them the right to use it indefinitely. Subscription models involve users paying a recurring fee to access and use the software or services. With this model, users usually do not own the software but have ongoing access to the latest versions and updates.

End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies

Contract research organizations (CROs) often utilize biosimulation to support their clients' drug discovery and development processes and offer services such as molecular modeling, PK/PD modeling, toxicity prediction, and trial design using biosimulation techniques. Pharmaceutical & biotechnology companies extensively employ biosimulation throughout the drug development pipeline. Regulatory authorities, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), play a crucial role in evaluating drug safety and effectiveness before being approved for market release. Regulatory authorities use biosimulation to assess the risk-benefit profile of drugs, optimize study designs, and make informed decisions during the drug approval process. Research institutes, including academic institutions and government organizations, employ biosimulation to advance scientific knowledge and conduct advanced research. Researchers utilize biosimulation tools and techniques to model and simulate complex biological systems, explore hypotheses, and gain insights into fundamental biological processes.

Application: Increasing application of biosimulation for drug development

Biosimulation plays a vital role in drug development by providing insights and predictions related to drug pharmacokinetic (PK) and pharmacodynamic (PD) properties, assisting in optimizing dosing regimens, predicting drug concentrations in target tissues, and assessing drug candidates' potential efficacy and safety. Biosimulation techniques, such as PBPK and PK/PD modeling, aid in making informed decisions during drug development. Biosimulation supports the design and optimization of clinical trials and enables the prediction and evaluation of drugs and chemical compounds' absorption, distribution, metabolism, excretion, and toxicity properties. Biosimulation helps identify potential ADME/Tox issues early in the drug development process, reducing the need for extensive animal testing and providing insights into potential risks. PK/PD modeling and simulation assist in predicting the relationship between drug exposure and response. Biosimulation supports lead identification & optimization by employing molecular modeling and simulation techniques. It aids in screening and evaluating potential drug candidates, predicting their binding affinity to target molecules, and optimizing their chemical structures for improved potency and selectivity. Biosimulation techniques aid in the identification and validation of potential drug targets. By modeling and simulating the interactions between drug molecules and target proteins, biosimulation helps evaluate the feasibility and potential effectiveness of targeting specific proteins.

Regional Insights

The Americas region showcases a highly developing landscape for the biosimulation market owing to the presence of major established players in the United States and their ongoing efforts to advance biosimulation software. Well-established regulatory authorities such as the Food and Drug Administration (FDA), European Medicines Agency (EMA), and Health Canada to ensure the safety and efficiency of drug development and clinical trials are benefiting the market growth across the Americas, Europe, and Asia-Pacific. Considering the EMEA region, the increasing investment in drug development and clinical trials across UK, Germany, and France is expanding the adoption of biosimulation software & services. The increasing number of chronic diseases across Asia-Pacific encourages government and regulatory authorities to expand their funding activities for drug development which is expected to create a platform for developing the biosimulation market. The presence of various initiatives such as Australia's Drug Discovery Initiative and Medical Research Commercialisation Initiative that aims at pharmaceutical research and development (R&D) activities is expanding the usage of biosimulation in Asia-pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Biosimulation Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Biosimulation Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Biosimulation Market, highlighting leading vendors and their innovative profiles. These include Advanced Chemistry Development, Inc., Aitia, Allucent, Applied BioMath, LLC, Biomed Simulation, Inc., BioSimulation Consulting Inc., Cadence Design Systems, Inc., Cell Works Group, Inc., Certara, Inc., Chemical Computing Group ULC, Compugen Ltd., Crystal Pharmatech Co., Ltd., Dassault Systemes SE, Genedata AG, Immunetrics Inc, In Silico Biosciences, Inc., INOSIM Software GmbH, Instem PLC, Laboratory Corporation of America Holdings, Model Vitals, Physiomics PLC, Quotient Sciences Limited, Resolution Medical, Rosa & Co LLC, Schrodinger, Inc., Simulations Plus, Inc., Thermo Fisher Scientific Inc., VeriSIM Life., VIRTUALMAN, and Yokogawa Electric Corporation.

Market Segmentation & Coverage

This research report categorizes the Biosimulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Services
      • Contract Services
      • In-House Services
    • Software
      • Molecular Modeling & Simulation Software
      • PBPK Modeling & Simulation Software
      • PK/PD Modeling & Simulation Software
      • Toxicity Prediction Software
      • Trial Design Software
  • Delivery Model
    • Ownership Models
    • Subscription Models
  • End-User
    • Contract Research Organizations
    • Pharmaceutical & Biotechnology Companies
    • Regulatory Authorities
    • Research Institutes
  • Application
    • Drug Development
      • Clinical Trials
      • Preclinical Testing
        • ADME/Tox
        • PK/PD
    • Drug Discovery
      • Lead Identification & Optimization
      • Target Identification & Validation
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Biosimulation Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Biosimulation Market?

3. What are the technology trends and regulatory frameworks in the Biosimulation Market?

4. What is the market share of the leading vendors in the Biosimulation Market?

5. Which modes and strategic moves are suitable for entering the Biosimulation Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing emphasis on research of personalized medicine
      • 5.1.1.2. Supportive regulatory approvals for use of biosimulation to enhance the development of safe medicines
    • 5.1.2. Restraints
      • 5.1.2.1. Upscaled prices involved in installations and technique developments for biosimulation
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in simulation solutions to enhance the novel biologic therapies
      • 5.1.3.2. Rising investments for drug developments and drug testings
    • 5.1.4. Challenges
      • 5.1.4.1. Lack of awareness coupled with complexities for creating accurate outcomes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Rising usage of software in biosimulation to provide a platform for model building, simulation, analysis, and visualization
    • 5.2.2. Delivery Model: Growing preference for ownership model in biosimulation for providing full control to users
    • 5.2.3. End-User: Expanding adoption of biosimulation among pharmaceutical & biotechnology companies
    • 5.2.4. Application: Increasing application of biosimulation for drug development
  • 5.3. Market Trend Analysis
    • 5.3.1. Significant investments in drug development and collaborative activities to expand the usage of biosimulation in the Americas
    • 5.3.2. Government initiatives to encourage the adoption of innovative technologies in pharmaceutical research in the APAC
    • 5.3.3. Increasing clinical trials and drug development activities expanding the scope of biosimulation in the EMEA region
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework Analysis

6. Biosimulation Market, by Offering

  • 6.1. Introduction
  • 6.2. Services
  • 6.3. Software

7. Biosimulation Market, by Delivery Model

  • 7.1. Introduction
  • 7.2. Ownership Models
  • 7.3. Subscription Models

8. Biosimulation Market, by End-User

  • 8.1. Introduction
  • 8.2. Contract Research Organizations
  • 8.3. Pharmaceutical & Biotechnology Companies
  • 8.4. Regulatory Authorities
  • 8.5. Research Institutes

9. Biosimulation Market, by Application

  • 9.1. Introduction
  • 9.2. Drug Development
  • 9.3. Drug Discovery

10. Americas Biosimulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Biosimulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Biosimulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Certara and DNDi Partnering to Fast-track Data Submissions and Accelerate Drug Approvals for Neglected Patients
    • 13.3.2. Certara Launches Version 8.4 of Phoenix Biosimulation Software for Drug Development
    • 13.3.3. Certara Amplifies CODEX Platform Capabilities with AI for Drug Discovery
    • 13.3.4. Simulations Plus Launches New Integrated Pulmonary Software and Services Package to Streamline Drug Development and Improve Patient Outcomes
    • 13.3.5. Simulations Plus Receives U.S. FDA Renewal for DILIsym Software Licenses
    • 13.3.6. Simulations Plus Enters Partnership to Apply AI/ML Technologies to Design Novel Compounds
    • 13.3.7. Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool
    • 13.3.8. Cellworks Expands into Precision Pharma to Accelerate the Development of Cancer Drugs and Revive Shelved Pharmaceutical Assets
    • 13.3.9. Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
    • 13.3.10. Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma
    • 13.3.11. Applied BioMath, LLC Announces a Continuation of their Collaboration with Celsius Therapeutics for Systems Pharmacology Modeling in Inflammatory Bowel Disease
    • 13.3.12. GNS and Servier Announce AI Collaboration to Advance Multiple Myeloma Drug Discovery and Clinical Development
    • 13.3.13. Cadence Expands into Molecular Simulation with Acquisition of OpenEye Scientific, a Pioneering Leader in Computational Molecular Design
    • 13.3.14. Resolution Medical Acquires LifeTec Group
    • 13.3.15. Colorcon Ventures Invests in AI-Driven Bio-simulation Company VeriSIM Life

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. BIOSIMULATION MARKET RESEARCH PROCESS
  • FIGURE 2. BIOSIMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. BIOSIMULATION MARKET DYNAMICS
  • FIGURE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA BIOSIMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. BIOSIMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. BIOSIMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOSIMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOSIMULATION MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL BIOSIMULATION MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL BIOSIMULATION MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL BIOSIMULATION MARKET SIZE, BY IN-HOUSE SERVICES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL BIOSIMULATION MARKET SIZE, BY MOLECULAR MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL BIOSIMULATION MARKET SIZE, BY PBPK MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD MODELING & SIMULATION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL BIOSIMULATION MARKET SIZE, BY TOXICITY PREDICTION SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL BIOSIMULATION MARKET SIZE, BY TRIAL DESIGN SOFTWARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL BIOSIMULATION MARKET SIZE, BY OWNERSHIP MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL BIOSIMULATION MARKET SIZE, BY SUBSCRIPTION MODELS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL BIOSIMULATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL BIOSIMULATION MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL BIOSIMULATION MARKET SIZE, BY REGULATORY AUTHORITIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL BIOSIMULATION MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL BIOSIMULATION MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 59. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 60. GLOBAL BIOSIMULATION MARKET SIZE, BY ADME/TOX, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 61. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 62. GLOBAL BIOSIMULATION MARKET SIZE, BY PK/PD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 63. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 64. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 65. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 66. GLOBAL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 67. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 68. GLOBAL BIOSIMULATION MARKET SIZE, BY LEAD IDENTIFICATION & OPTIMIZATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 69. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 70. GLOBAL BIOSIMULATION MARKET SIZE, BY TARGET IDENTIFICATION & VALIDATION, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 73. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 74. AMERICAS BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 75. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 76. AMERICAS BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 77. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 78. AMERICAS BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 79. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 80. AMERICAS BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 81. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. AMERICAS BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 84. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 85. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 86. AMERICAS BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 87. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 88. AMERICAS BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 89. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 90. AMERICAS BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 91. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 92. ARGENTINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 93. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 94. ARGENTINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 95. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 96. ARGENTINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 97. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 98. ARGENTINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 99. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 100. ARGENTINA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 101. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 102. ARGENTINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 103. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 104. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 105. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 106. ARGENTINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 107. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 108. ARGENTINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 109. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 110. BRAZIL BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 111. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 112. BRAZIL BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 113. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 114. BRAZIL BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 115. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 116. BRAZIL BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 117. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 118. BRAZIL BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 119. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 120. BRAZIL BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 121. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 122. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 123. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 124. BRAZIL BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 125. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 126. BRAZIL BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 127. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 128. CANADA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 129. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 130. CANADA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 131. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 132. CANADA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 133. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 134. CANADA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 135. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 136. CANADA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 137. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 138. CANADA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 139. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 140. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 141. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 142. CANADA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 143. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 144. CANADA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 145. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 146. MEXICO BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 147. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 148. MEXICO BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 149. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 150. MEXICO BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 151. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 152. MEXICO BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 153. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 154. MEXICO BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 155. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. MEXICO BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 158. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 159. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 160. MEXICO BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 161. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 162. MEXICO BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 163. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 164. UNITED STATES BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 165. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 166. UNITED STATES BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 167. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 168. UNITED STATES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 169. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 170. UNITED STATES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 171. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 172. UNITED STATES BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 173. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. UNITED STATES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 176. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 177. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 178. UNITED STATES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 179. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 180. UNITED STATES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 181. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 182. UNITED STATES BIOSIMULATION MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC BIOSIMULATION MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 203. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 204. AUSTRALIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 205. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 206. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 207. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 208. AUSTRALIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 209. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 210. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 211. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 212. AUSTRALIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 213. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. AUSTRALIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 216. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 217. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 218. AUSTRALIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 219. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 220. AUSTRALIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 221. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 222. CHINA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 223. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 224. CHINA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 225. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 226. CHINA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 227. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 228. CHINA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 229. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 230. CHINA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 231. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. CHINA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 234. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 235. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 236. CHINA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 237. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 238. CHINA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 239. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 240. INDIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 241. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 242. INDIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 243. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 244. INDIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 245. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 246. INDIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 247. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 248. INDIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 249. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 250. INDIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 251. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 252. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 253. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 254. INDIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 255. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 256. INDIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 257. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 258. INDONESIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 259. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 260. INDONESIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 261. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 262. INDONESIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 263. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 264. INDONESIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 265. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 266. INDONESIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 267. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 268. INDONESIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 269. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 270. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 271. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 272. INDONESIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 273. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 274. INDONESIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 275. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 276. JAPAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 277. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 278. JAPAN BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 279. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 280. JAPAN BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 281. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 282. JAPAN BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 283. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 284. JAPAN BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 285. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. JAPAN BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 288. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 289. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 290. JAPAN BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 291. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 292. JAPAN BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 293. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 294. MALAYSIA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 295. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 296. MALAYSIA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 297. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 298. MALAYSIA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 299. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 300. MALAYSIA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 301. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 302. MALAYSIA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 303. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 304. MALAYSIA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 305. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 306. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 307. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 308. MALAYSIA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 309. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 310. MALAYSIA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 311. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 312. PHILIPPINES BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 313. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 314. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 315. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 316. PHILIPPINES BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 317. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 318. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 319. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 320. PHILIPPINES BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 321. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 322. PHILIPPINES BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 323. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 324. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 325. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 326. PHILIPPINES BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 327. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 328. PHILIPPINES BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 329. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 330. SINGAPORE BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 331. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 332. SINGAPORE BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 333. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 334. SINGAPORE BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 335. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 336. SINGAPORE BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 337. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 338. SINGAPORE BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 339. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 340. SINGAPORE BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 341. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 342. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 343. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 344. SINGAPORE BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 345. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 346. SINGAPORE BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 347. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 348. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 349. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2018-2023 (USD MILLION)
  • TABLE 350. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SERVICES, 2024-2030 (USD MILLION)
  • TABLE 351. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2018-2023 (USD MILLION)
  • TABLE 352. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY SOFTWARE, 2024-2030 (USD MILLION)
  • TABLE 353. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2018-2023 (USD MILLION)
  • TABLE 354. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DELIVERY MODEL, 2024-2030 (USD MILLION)
  • TABLE 355. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2018-2023 (USD MILLION)
  • TABLE 356. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY END-USER, 2024-2030 (USD MILLION)
  • TABLE 357. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 358. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 359. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2018-2023 (USD MILLION)
  • TABLE 360. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DEVELOPMENT, 2024-2030 (USD MILLION)
  • TABLE 361. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2018-2023 (USD MILLION)
  • TABLE 362. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY PRECLINICAL TESTING, 2024-2030 (USD MILLION)
  • TABLE 363. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2018-2023 (USD MILLION)
  • TABLE 364. SOUTH KOREA BIOSIMULATION MARKET SIZE, BY DRUG DISCOVERY, 2024-2030 (USD MILLION)
  • TABLE 365. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 366. TAIWAN BIOSIMULATION MARKET SIZE, BY OFFERING,